Long-Term Outcomes of S-1 Combined With Low-Dose Docetaxel as Neoadjuvant Chemotherapy (N-1 Study, Phase II Trial) in Patients With Operable Breast Cancer

CONCLUSION: Our NAC regimen achieved favorable long-term outcomes and significantly improved OS in the pCR group. High TILs, NG 2-3, and some miRNAs may be predictors of pCR.PMID:38462397 | DOI:10.1016/j.clbc.2024.02.014

Source: Clinical Genitourinary Cancer - March 10, 2024 Category: Cancer & Oncology Authors: Soichiro Sasa Hiroaki Inoue Misako Nakagawa Hiroaki Toba Masakazu Goto Kazumasa Okumura Mariko Misaki Tomohiro Inui Sawaka Yukishige Aya Nishisho Naoki Hino Miyuki Kanematsu Yoshimi Bando Hisanori Uehara Akira Tangoku Hiromitsu Takizawa Source Type: research